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The aim of this study was to identify a high-affinity BODIPY
peptidomimetic that targets the prostate-specific membrane
antigen (PSMA) as a potential bimodal imaging probe for
prostate cancer. For the structure-activity study, several BODIPY
(difluoroboron dipyrromethene) derivatives with varying
spacers between the BODIPY dye and the PSMA Glu-CO-Lys
binding motif were prepared. Corresponding affinities were
determined by competitive binding assays in PSMA-positive
LNCaP cells. One compound was identified with comparable
affinity (IC50=21.5�0.1 nM) to Glu-CO-Lys-Ahx-HBED-CC
(PSMA-11) (IC50=18.4�0.2 nM). Radiolabeling was achieved by
Lewis-acid-mediated 19F/18F exchange in moderate molar activ-
ities (~0.7 MBqnmol  1) and high radiochemical purities (>99%)
with mean radiochemical yields of 20–30%. Cell internalization
of the 18F-labeled high-affinity conjugate was demonstrated in
LNCaP cells showing gradual increasing PSMA-mediated inter-
nalization over time. By fluorescence microscopy, localization of
the high-affinity BODIPY-PSMA conjugate was found in the cell
membrane at early time points and also in subcellular compart-
ments at later time points. In summary, a high-affinity BODIPY-
PSMA conjugate has been identified as a suitable candidate for
the development of PSMA-specific dual-imaging agents.
Introduction
Optical fluorescence imaging represents an integral part of
modern clinical oncology and provides numerous advantages
for cancer detection, staging, characterization or therapy
response assessment, including a high spatial resolution, a high
portability as well as a detailed molecular profiling.[1] Because of
its inherent properties, such as real-time readout, the produc-
tion of high-resolution images, an easy complementation with
other imaging modalities and the possibility to detect multiple
signals concomitantly, fluorescence imaging is also suitable for
tumor resection in targeted surgery.[2,3] With the emergence of
optical fluorescent imaging modalities as well as advanced
in vivo or in vitro microscopy techniques in oncology and
biomedical research, various fluorescent probes have been
developed for targeting biological structures.[4,5] Besides a large
variety of sensors based on fluorescent proteins,[4,6–8] a fluores-
cent probe typically consists of small organic fluorophores[9,10]
or lanthanide complexes,[11,12] which allows in combination with
a tumor-specific vector the design of highly sensitive targeting
probes for several cancer entities.[13] Among the large set of
highly fluorescent probes in oncology and cancer research,[14–16]
the class of sensors based on the 4,4-difluoro-4-bora-3a,4a-
diaza-s-indacene (difluoroboron dipyrromethene=BODIPY)
scaffold given in Scheme 1A shows great potential for imaging
applications.[4,17,18] Since the first report of BODIPY dyes by
Treibs and Kreuzer in 1968,[19] these dyes have become more
and more popular in imaging techniques due to their ease of
synthesis and their beneficial spectroscopic properties. BODIPY
dyes show resistance towards self-aggregation and have high
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Scheme 1. A) difluoroboron dipyrromethene (BODIPY) scaffold. B) BODIPY
dyes 1 with a carboxylic acid functionality for bioconjugation and its
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photostability, high molar absorption coefficients and
fluorescence quantum yields as well as emission wavelengths in
the visible spectral region with narrow absorption and emission
bands and a small Stokes shift.[18,20–23] Moreover, synthetic
BODIPY core modifications enable the facile variation of the
photophysical, spectroscopic and chemical properties, improv-
ing the biological compatibility.[17,18,20,21,24] BODIPY-based sensors
for biomedical research were successfully used for specific
imaging of subcellular compartments, as sensitive imaging
probes for various tumor-related receptors or overexpressed
target proteins as well as for screening to identify key
biomolecules for selective imaging and visualization of bio-
logical processes.[4,25–28] Furthermore, the BODIPY core can be
modified to facilitate singlet oxygen generation for the
potential use in photodynamic therapy.[29] However,
fluorescence imaging suffers from limited tissue penetration
depths, a fact that still prevents the use of this technology for
whole-body-scanning in humans.[2,30] One possible solution of
this limitation is the combination of fluorescence imaging with
nuclear imaging techniques, such as single photoemission
computed tomography (SPECT) or positron emission tomogra-
phy (PET), or anatomical imaging modalities such as magnetic
resonance imaging (MRI).[31–33] PET is a non-invasive whole-body
imaging modality, that detects pairs of gamma rays, a
secondary product of the positron annihilation.[2,34,35] A combi-
nation of fluorescence with nuclear imaging would thus allow
imaging from the whole-body down to the subcellular level,
making the development of dual-modality probes an active
field of research.[34] A major advantage of the BODIPY scaffold is
the possibility to introduce the positron emitting radionuclide
fluorine-18 by Lewis-acid assisted isotopic 19F/18F exchange
combining a fluorescent and a nuclear probe in a single
entity.[34,36–38] In this respect, the potential of BODIPY dyes for
the development of dual-imaging probes has recently been
reviewed.[37]
Here, we report on the development of hybrid PET and
optical probes based on the BODIPY scaffold targeting the
prostate-specific membrane antigen (PSMA) for potential use as
dual imaging probes for prostate cancer (PCa). PSMA, also
known as glutamate carboxypeptidase type II (GCP II), is a 750-
residue type II transmembrane glycoprotein that has become a
valuable molecular target for PCa imaging and therapy due to
its selective upregulation in PCa lesions, such as lymph node as
well as bone metastases.[39–3] PSMA is also a prognostic factor
for disease recurrence.[44] With the emergence of radiolabeled
urea-based probes in nuclear medicine, imaging of PCa by PET/
CT (computed tomography) has become increasingly important
for staging, restaging, and treatment selection and had a
tremendous impact on the diagnosis, treatment planning,
therapy monitoring as well as for endoradiotherapy of PCa
patients.[45–52] Additionally, radiolabeled bimodal PSMA inhib-
itors are currently the subject of intensive research with
promising results in several preclinical studies towards hybrid
imaging of PCa.[53,54] More recently, the (sub)cellular fate of
peptidomimetic PSMA inhibitors was studied using stimulated
emission depletion (STED) nanoscopy.[55] PSMA-specific internal-
ization of bimodal PSMA inhibitors is mediated via clathrin-
dependent endocytosis and a homogenous distribution of the
PSMA inhibitors in the cytoplasm was found over time.
To the best of our knowledge, a radiolabeled BODIPY-PSMA
conjugate for dual-imaging of PCa has not been described to
date. Alquicer et al. reported on the fluorescent probe TMR-X-
Lys-urea-Glu comprising a BODIPY fluorophore for the identi-
fication of new GCP II targeting ligands by high-throughput
fluorescence polarization assays.[56] More recently, Son et al.
have reported on a PSMA conjugate comprising the NIR dye
BODIPY650/665 with about ten-fold lower affinity than the potent
PSMA inhibitor ZJ-43. The BODIPY-PSMA conjugate showed
specific uptake in PSMA-expressing cells and allowed visual-
ization of PSMA-positive tumors in a mouse model by optical
imaging.[57] However, radiolabeling with fluorine-18 and/or
small-animal PET imaging were not reported.
To identify a high-affinity BODIPY-PSMA conjugate, we
synthesized a small series of peptidomimetic BODIPY-PSMA
conjugates with various spacer entities to establish a structure-
activity relationship. Simultaneously, we also optimized the
chemical syntheses due to the sensitivity of the BODIPY scaffold
to acidic reaction conditions. We furthermore report on the
effect of the peptidomimetic PSMA-binding motif on the
spectroscopic properties of the BODIPY dye 1 (Scheme 1B), the
radiofluorination of corresponding BODIPY-PSMA conjugates 3–
6, and their biological evaluation in the PSMA-expressing LNCaP
cell line with regards to binding affinity and cell internalization.
This way, a BODIPY-PSMA conjugate could be identified that




For the preparation of the series of BODIPY-PSMA conjugates, a
mix of solid-phase and solution-based chemistry was performed
to take advantage of the rapid and efficient coupling reactions
on solid support while avoiding the acid-catalyzed decomposi-
tion of the BODIPY dye (Scheme 2). First, the Glu-CO-Lys PSMA
binding motif was synthesized on solid support according to
literature methods with minor modifications.[45] Here, 1,1’-
carbonyldiimidazole (CDI) instead of triphosgene was used for
the build-up of the Glu-CO-Lys moiety.[58] Additional amino acid
spacers were consequently introduced stepwise by standard
Fmoc-protected peptide chemistry using HATU (O-(7-Azabenzo-
triazol-1-yl)-N,N,N’,N’-tetramethyluronium-hexafluorphosphate)/
DIPEA (N,N-diisopropylethylamine) to prepare intermediates for
conjugation of the BODIPY dye 1 in solution.[50] For the structure
activity relationships studies, four different spacer entities were
prepared. To gain insight into the optimal distance between
the Glu-CO-Lys moiety and the BODIPY dye 1, either no spacer,
one or two 6-aminohexanoic acid residues were introduced. For
the fourth derivative, a 2-naphthylalanin-aminometh-
ylcyclohexylic acid (2-Nal-Amc) spacer similar to the spacer of
PSMA-617 was used.[50] It is well-known that BODIPY dyes are
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conditions required during solid phase peptide synthesis, e.g.
acid-catalyzed deprotection and cleavage from the resin using
trifluoroacetic acid (TFA). To circumvent the formation of side
products, corresponding Glu-CO-Lys conjugates were thus
deprotected and cleaved from the resin using a cocktail of TFA/
H2O/triisopropylsilane (95/2.5/2.5, % v/v) prior to the conjuga-
tion of the BODIPY dye.
For our studies, we selected the BODIPY derivative 1 as
fluorophore, shown in Scheme 1B, as it is readily synthesized
and offers a carboxylic acid group allowing covalent conjuga-
tion of a targeting vector via peptide bond formation.
Compound 1 was prepared according to the literature.[63,64] By
minor modifications of the reaction conditions and the workup
process, the yield could be increased from 21% in the original
synthesis to 55% in this work.[63] Compound 1 was also
transformed into the corresponding NHS ester 2 to obtain a
BODIPY derivative that can readily be coupled to a suitable
targeting vector without the addition of a coupling agent
(Scheme 1B). By dilution of 2 in acetone and slow evaporation
of the solvent at ambient temperature, orange crystals were
obtained, which were suitable for X-ray analysis (CCDC number:
2054523).
A graphical representation of the crystal structure of 2 is
given in Figure 1 and corresponding crystallographic data is
provided in the Supporting Information. Structural features are
comparable to literature reports with BODIPY moiety formed by
three conjugated heterocyclic rings (the central six-membered
ring with two adjacent five-membered rings) being almost
planar.[63] Conjugation of 1 to the Glu-CO-Lys binding motifs
with different spacer entities was performed in solution using
two different coupling methods. Either compound 1 together
with HATU or the NHS derivative 2 were reacted with
corresponding PSMA conjugates in the presence of DIPEA. This
way, BODIPY-PSMA conjugates 3–6 were obtained in overall
yields of 37–44% after purification by semi-preparative HPLC,
respectively. No significant differences in terms of coupling
efficiency between compound 1 and HATU vs. NHS ester 2 were
noted. Final bioconjugates 3–6 were fully characterized by one-
and two-dimensional 1H, 13C, 19F-NMR spectroscopy, mass
spectrometry, fluorescence spectroscopy, and analytical HPLC.
Corresponding data are provided in the Supporting Informa-
tion.
Fluorescence spectroscopy measurements
To investigate if conjugation of compound 1 to the targeting
vectors impacted the fluorescence properties, additional
fluorescence spectroscopy measurements of 3–6 in acetonitrile/
water (1 :1, v/v) were performed (Table 1). As can be seen from
the results in Table 1 and Figure S27, the PSMA-targeting
peptidomimetics did not alter the absorption or the emission
maxima of 3–6, with wavelengths in the range of λabs=494 nm
to λabs=496 nm and λem=504 nm to λem=506 nm, respectively.
We also examined the fluorescence quantum yield ϕFl and the
fluorescence lifetime τFl. Conjugation of 1 to the PSMA ligands
did not impact the fluorescence lifetime of 3–6 being in the
same nanosecond range as for compound 1 (Table 1/Fig-
ure S27+S28). A faint increase of the fluorescence quantum
yields of 3–6 compared to 1 could be the result of the
transformation of the carboxylic acid group into an amide
Scheme 2. Synthetic procedure for the preparation of BODIPY-PSMA bioconjugates 3–6 using a combination of solid-phase and solution-based chemistry.
Figure 1. ORTEP representation of 2 with thermal ellipsoids drawn at 50%
probability level.
Table 1. Spectroscopic data of 1 and BODIPY-PSMA conjugates 3–6 in
acetonitrile/water (1 : 1, v/v).
Compd λabs [nm] λexc [nm] λem [nm] ϕFl [%] τFl [ns]
1 494 496 505 75�5 6.3�0.1
3 495 496 506 81�5 5.9�0.1
4 496 496 506 86�5 6.1�0.1
5 496 496 506 81�5 6.2�0.1
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circumventing a potential negative charge in close proximity to
the dipyrromethene core.
Studies on BODIPY stability
During the establishment of the synthetic routes of the BODIPY-
PSMA conjugates 3–6 and the radiolabeling experiments, we
observed the decomposition of the BODIPY fluorophore under
acidic conditions. For example, when performing the syntheses
entirely on solid support and cleaving corresponding BODIPY-
PSMA conjugates from the resin using a TFA/H2O/triisopropylsi-
lane (95/2.5/2.5, % v/v) cocktail, we isolated fractions by HPLC
that eluted prior to the product peaks and that differed by a
mass difference of m/z=-48 in the mass spectrometry com-
pared to the intact compounds confirming loss of the BF2-core
(Figure S25). To investigate the stability of the BODIPY dye
under these conditions in more detail, compound 1 was
incubated in 95% TFA and samples were measured by
fluorescence spectroscopy for up to 24 h (Figure 2A+B). While
the absorption spectra of 1 in TFA only showed a small blue-
shift of maxima from λabs=496 nm to λabs=488 nm (Figure 2A),
a significant change of corresponding emission spectra was
noted. After a few seconds of the incubation process a slight
red shift from λem=509 nm to λem=515 nm is observed (Fig-
ure 2B), probably due to the initial coordination of a proton to a
nitrogen atom of the BODIPY core. Within 2 h a steady decrease
of the emission intensity was noted, presumably as a result of
the proton-mediated loss of the BF2 moiety. At 24 h, the
emission intensity was quenched completely, while the absorp-
tion intensity was still observable. The plot of the emission
intensity vs. time gave the decay curve in Figure S34. From a
tentative biexponential fit, two kinetic constants for decom-
position/fading with k=0.168�0.011 min and k=0.018�
0.006 min were obtained. Corresponding half-lives of 1 in TFA
were calculated to τ1/2=4.1�0.3 min and τ1/2=37.9�9.4 min.
Our results are in agreement with results from Rumyantsev,
who postulated a two-step dissociation process of BODIPY
complexes with a rapid protonation of the BODIPY core
followed by a slow release of BF2 unit.
[60,61] We therefore confirm
that proton coordination finally results in the release of the BF2
unit, while the chromophore remained intact. This finding is
corroborated by the observation that fluorescence can widely
be restored after 24 h upon addition of BF3-diethyletherate
(data not shown). The TFA-mediated loss of the BF2 entity of
compound 1 was also confirmed by analytical HPLC and MS
(Figures S33B–S34). A similar finding was observed in the HPLC
chromatograms of the 18F-labeling reactions (vide infra).
18F-labeling, stability measurements and log Doct/PBS
determination
Next, the bioconjugates 3–6 were labeled at room temperature
with 18F via Lewis-acid assisted 19F/18F isotopic exchange in dry
acetonitrile using tetraethylammonium-[18F]fluoride ([18F]F-TEA)
and SnCl4 within 15 min incubation.
[34,38] A representative
scheme of the radiolabeling process is given in Scheme 3 for
compound 4. Optimization of the labeling conditions included
variation of the reaction temperature and the amount of SnCl4.
The highest radiochemical yields (RCYs) were achieved when a
100-fold molar excess of SnCl4 compared to the labeling
precursor was used. An increase of the labeling temperature to
37 °C or 95 °C or higher amounts of SnCl4 (e.g. 500 eq.) did not
result in an increase of RCYs. Under optimized labeling
conditions, [18F]F-3, [18F]F-4, [18F]F-5 and [18F]F-6 were obtained
in radiochemical yields of 20–30% and radiochemical purities
(RCP) of >99%. The mean molar activities Am were
~0.7 MBq ·nmol  1. Following the labeling reactions, the radio-
Figure 2. Normalized A) absorption and B) emission spectra (λexc=460 nm)
of 1 in 95% TFA at different time points. Normalized C) absorption and D)
emission spectra (λexc=460 nm) of 1 in 1 M SnCl4 in acetonitrile at different
time points.
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labeled products [18F]F-3, [18F]F-4, [18F]F-5 and [18F]F-6 were
purified by C18 SepPak cartridges and reconstituted in saline
(5% EtOH) for further experiments. While the RCPs were >99%,
an additional peak in the UV/vis trace of the HPLC chromato-
grams of [18F]F-3, [18F]F-4, [18F]F-5 and [18F]F-6 was observed,
which matched the HLPC trace of the BF2-free conjugates. This
finding is exemplarily shown for [18F]F-4 in Figure 3.
To gain more insight, the impact of the Lewis acid SnCl4,
again on the decomposition of the precursor 1, was inves-
tigated in acetonitrile by UV/vis and fluorescence spectroscopy
(Figure 2C+D). The corresponding emission spectra showed a
bathochromic shift of the maximum from λem=509 nm to λem=
520 nm compared to intact 1 immediately after dissolving in
the SnCl4 solution (Figure 2D). Moreover, a second emission
band with λem=545 nm was noted, which can unambiguously
be traced back to an excitation maximum at λexc=530 nm
(Figure S29). A similar observation was made for corresponding
absorption spectra with an initial red shift and formation of a
second absorption band varying slightly over the course of the
measurements (Figure 2C). These changes might be attributed
to the formation of an intermediate between the Lewis acid
and the fluorine atoms of 1.[36] Another possible explanation
could be the substitution of fluoride with chloride or even an
insertion of SnClx. At least, both the pronounced spectral shift
and the maintained fluorescence hint to distinctly disturbed,
but still intact chromophore with a bridging heteroatom
between the two pyrrole moieties. In summary, the acidic
conditions for radiolabeling, mainly due to the Lewis acid SnCl4
and subsequent aqueous work-up, also resulted in the partial
loss of the BF2 core, which occurred to 5% to 10% depending
on the reaction conditions. When higher amounts of SnCl4 were
used, formation of by-products increased. These impurities,
however, could easily be separated from the 18F-labeled
bioconjugates by HPLC. And even more important, once
formed, no degradation or formation of (radioactive) by-
products of HPLC-purified [18F]F-4 was observed in phosphate
buffered saline (PBS) at pH 7.4 for 2 h, and the RCP was still
>97% after this incubation time, indicating high stability of the
radiotracer.
An important indicator for the pharmacokinetics and target
affinity is the lipophilicity of PSMA radiotracers. Thus, partition
coefficients log Doct/PBS between 1-octanol and PBS were
determined for compounds [18F]F-3-6. Corresponding log Doct/PBS
values of [18F]F-3-6 and [68Ga]Ga-PSMA-11 together with corre-
sponding HPLC retention times are listed in Table 2. In the
series of fluorine-18 labeled compounds [18F]F-3-6, log Doct/PBS
values increased with increasing spacer lengths. The results are
furthermore corroborated by the analytical RP-HPLC retention
times. Compound [18F]F-3 with no spacer was the most hydro-
philic compound, while the introduction of additional Ahx
spacers resulted in a gradual increase of the lipophilicity for
[18F]F-4 and [18F]F-5, respectively. As expected, compound [18F]F-
6 exhibited the highest lipophilicity due to the lipophilic 2-NaI-
Amc spacer. In comparison to the clinical gold standard [68Ga]
Ga-PSMA-11, all BODIPY-PSMA were more lipophilic.
In vitro characterization
In order to identify a BODIPY-PSMA conjugate with high target
affinity, a small series of compounds was prepared with
differing spacer lengths and composition. To establish a
structure-activity relationship, the binding affinities of BODIPY-
PSMA conjugates 3–6 were thus determined in the PSMA-
positive human prostate cancer cell line LNCaP by a competitive
binding assay as previously reported using [177Lu]Lu-PSMA-617
as radioligand.[65] Glu-CO-Lys-Ahx-HBED-CC, the uncomplexed
precursor of [68Ga]Ga-PSMA-11, was included as the control.[50]
Corresponding IC50 values of bioconjugates 3–6 and Glu-CO-
Lys-Ahx-HBED-CC are summarized in Table 3.
In the series of BODIPY-PSMA conjugates, compound 4 with
an Ahx spacer exhibited the highest affinity with an IC50=
21.5�0.1 nM being comparable to the control PSMA-11 with
IC50=18.4�0.2 nM. Using the Cheng-Prusoff equation, an
inhibitory constant of Ki=19.6 nM for 4 was calculated, which is
comparable to the Ki of
natGa-Glu-CO-Lys-Ahx-HBED-CC (natGa-
PSMA-11) with 12.0 nM.[45] This could be explained by the
structural analogy between 4 and Glu-CO-Lys-Ahx-HBED-CC. As
Figure 3. A) Representative UV/vis HPLC chromatogram of 4 (insert: MS
spectrum of 4). B) Radio-HPLC chromatogram of [18F]F-4. C) Representative
UV/vis HPLC chromatogram of 4 without BF2 (insert: MS spectrum of 4 -BF2).
D) UV/vis HPLC chromatogram of [18F]F-4 showing loss of the BF2 entity
during radiolabeling by Lewis acid mediated isotopic 19F/18F isotopic
exchange.
Table 2. Analytical HPLC retention times and log Doct/PBS values of
bioconjugates [18F]F-3-6 together with the reference compound [68Ga]Ga-
PSMA-11.
Compound tR [min] log Doct/PBS
[18F]F-3 11.26   2.26�0.02
[18F]F-4 11.39   1.99�0.11
[18F]F-5 11.50   1.35�0.01
[18F]F-6 12.96   1.14�0.06
[68Ga]Ga-PSMA-11 n.d.   2.91[a]
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discussed above, both ligands are using an Ahx linker between
the PSMA binding motif and the radiolabel. Furthermore, the
metal chelator HBED-CC and the BODIPY dye do both possess
lipophilic aromatic ring systems,[45] which are required for an
optimal interaction with the S1 pocket and the S1 accessory
pocket of the PSMA active site.[40,66,67] The BODIPY scaffold might
additionally interact with the arene-binding site close to the
entrance funnel of the internal PSMA cavity.[66,68] In contrast, the
binding affinity significantly decreased for compound 3 (IC50=
187.6�0.5 nM) with a shorter distance between the Glu-CO-Lys
PSMA binding motif and the BODIPY dye, most likely due to
steric hindrance preventing optimal accommodation of the
conjugate into the PSMA binding pocket. Further elongation of
the spacer by two Ahx moieties as for compound 5 also
resulted in lower affinity (IC50=96.4�0.2 nM), indicating that
this distance is most likely too long for optimal interaction of
the lipophilic BODIPY dye with the lipophilic accessory pocket
of PSMA. Surprisingly, compound 6 with a 2-Nal-Amc spacer
similar to PSMA-617 showed lower affinity with a IC50=124.0�
0.2 nM compared to PSMA-11. In case of 6, the low affinity
might be a result of its high overall lipophilicity (Table 2). The 2-
Nal-Amc-spacer has been found to bind nicely into the hydro-
phobic arginine patch of the S1 accessory pocket and the
distance between the PSMA binding motif and the radiolabel/
fluorescent tag for the 2-Nal-Amc-spacer appears to be optimal
for PSMA-617. However, in combination with the BODIPY
scaffold the overall lipophilicity of compound 6 is substantially
increased resulting in a significant reduction of binding affinity
(Table 3).[50,66,69] Because of the partial release of BF2 during the
isotopic 19F/18F-exchange reaction, we additionally determined
the binding affinity of the BF2-free analog of 4 because this side
product might compete with the bimodal probe in terms of
PSMA binding. Interestingly, the binding affinity of BF2-free 4 (4
- BF2) diminished completely with an IC50 value of >1 μM
indicating that BF2-free side product of 4 will not interfere with
binding of the radiotracer [18F]F-4 to PSMA.
In addition to the competitive binding studies, we also
investigated the internalization of [18F]F-4 into LNCaP cells for
up to 2 h. To determine PSMA-specific cell internalization,
additional blocking experiments were performed using 2-
(phosphonomethyl)-pentanedioic acid (2-PMPA), a highly spe-
cific PSMA inhibitor.[53] A graphical representation of the PSMA-
mediated internalization and PSMA-specific cell-surface binding
of [18F]F-4 is given in Figure 4. Given P values apply to
differences between blocked and unblocked experiments. As
expected, the PSMA-mediated internalized fraction of [18F]F-4
increased gradually over time. At 15 min and 30 min, [18F]F-4
was internalized to 2.24% and 2.17% (P<0.0057), respectively,
which further increased to 3.3% at 60 min (P<0.0015). The
maximum was reached at 120 min with 3.83% of [18F]F-4 being
internalized (P<0.0002). In contrast, the specific surface bound
fraction of [18F]F-4 remained essentially constant over the
course of the experiment with ~0.5%.
The specific cell surface binding and internalization of 4 in
LNCaP cells at different time points was also visualized by
fluorescence microscopy using a structured illumination micro-
scope (SIM) (Figure 5). PSMA-mediated uptake of compound 4
into LNCaP cells was confirmed by fluorescence microscopy
demonstrating gradual internalization over the period of 1 h. At
15 min, a significant accumulation of 4 was found in the cell
membrane of the LNCaP cells, in which the large extracellular
domain of the expressed PSMA is located (Figure 5A). At later
time points (30 min and 1 h), an increasing number of intra-
cellular fractions of high intensity was noted (Figure 5B+C),









Figure 4. PSMA-specific surface bound and internalized fractions of [18F]F-4
in LNCaP cells. Values are given as mean�SD. Results are from two
independent experiments in triplicate.
Figure 5. PSMA-mediated uptake of 4 into LNCaP cells, confirmed by SIM-
fluorescence microscopy over time at 25 °C at A) 15 min, B) 30 min, C) 1 h, D)
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being in concordance with the results of the cell internalization
experiment using [18F]F-4. Internalization of compound 4 occurs
presumably via clathrin-coated pits and subsequent endocyto-
sis after interaction with PSMA.[70] Moreover, our results are in
line with a recent study by Eder et al., which investigated the
subcellular fate of bimodal PSMA inhibitors in more detail by
STED nanoscopy.[55] At 4 °C, accumulation of 4 in the cell
membrane was observed. To further demonstrate the specificity
of the surface binding and internalization of 4, we also used 2-
PMPA for blocking studies (Figure 5E). After incubation with
excess 2-PMPA, neither specific accumulation in the membrane
nor internalization were observed, indicating PSMA-specific
membrane accumulation and cellular internalization. The visible
intracellular signals in the blocking study are caused by the
autofluorescence of the cell compartments as can be seen from
the negative control of fixed cells without addition of com-
pound 4 (Figure 5F).
Conclusion
In this work, we successfully introduced a synthetic strategy for
the preparation of four BODIPY-labeled PSMA-targeting vectors
using a combination of standard solid-phase- and liquid
synthesis techniques. The introduction of a peptidomimetic
PSMA-targeting moiety in this context did not alter fluorescent
properties of the dye and afforded bioconjugates with high
fluorescence quantum yields as well as fluorescence lifetimes
equal to the BODIPY carboxylic acid 1. The ligands 3–6 were
radiolabeled by Lewis acid-assisted isotopic 19F/18F exchange in
high radiochemical purities >99% with moderate molar
activities. In competitive cell binding and internalization experi-
ments, a BODIPY-PSMA conjugate was identified with compara-
ble PSMA affinity to Glu-CO-Lys-Ahx-HBED-CC, the precursor of
clinical imaging standard [68Ga]Ga-PSMA-11. Cellular localization
of 4 was also studied by fluorescence microscopy. Altogether,
results make compound 4 a promising candidate for further
development of PSMA-specific dual-imaging agents and sup-
port its future evaluation in vivo.
Experimental Section
General
Chemicals and solvents were purchased from Sigma-Aldrich,
Carbolution, Iris Biotech, Carl Roth, ABX advanced biochemical
compounds GmbH and TCI Europe, and used as received. Fluorine-
18 was obtained from Life Radiopharma Fcon GmbH (Holzhausen
a.d. Heide, Germany). Solvents used were dried using common
laboratory methods. All air-sensitive reactions were carried out
under a nitrogen atmosphere. NMR spectra were recorded in
CD3OD or CDCl3 at room temperature using an Avance II
spectrometer from Bruker BioSpin (400, 376 or 100 MHz). Chemical
shifts are given in parts per million (ppm) and are reported relative
to trimethylsilane (TMS). Coupling constants are reported in Hertz
(Hz). The multiplicity of the NMR signals is described as follows: s=
singlet, d=doublet, t= triplet, q=quartet, m=multiplet. 1H and 13C
spectra were referenced to residual protonated solvents, 19F spectra
were measured with external standard TFA. High performance
liquid chromatography (HPLC) was performed on a Shimadzu LC-
20AT system equipped with a Shimadzu SPD-20 A UV detector (UV
detection at 490 nm) and a Raytest Ramona radiation detector
(Raytest GmbH, Straubenhardt, Germany) in series. A Prontosil
column (250×4 mm) was used for analytical HPLC. The solvent
system was A=H2O (0.1% TFA) and B=acetonitrile (0.1% TFA). The
gradient was 0–1 min 5% B, 1–15 min 5–95% B, 15   17 min 95% B
at a flow rate of 1 mL ·min  1. Semi-preparative HPLC was performed
on a Techlab HPLC system in combination with a VDSpher 100 C18-E
column (250×20 mm), with A=H2O (0.1% TFA) and B=acetonitrile
(0.1% TFA) as the solvent system. Gradients used for semi-
preparative HPLC, the corresponding retention times, synthesis
yields, and characterization data for each compound are given
below. Samples were lyophilized using a Christ Alpha 1–2 LD plus
lyophilizer. Analytical thin-layer chromatography (TLC) was per-
formed on 0.2 mm silica gel 60 with fluorescence indicator pre-
coated aluminium sheets (40×80 mm, Macherey Nagel). Column
chromatography was carried out on silica gel 60 (230-400 mesh
particle size, technical grade, Sigma Aldrich). High resolution mass
spectrometry ((+)-HR-ESI-MS) was performed on an AB Sciex API
5500 QTRAP spectrometer. For low resolution mass spectrometry
((+)-LR-ESI-MS) an Advion expression CMS system was used. UV/Vis
spectroscopy was performed using a JASCO V-650 absorption
spectrometer. Fluorescence- and excitation spectra were recorded
with a JASCO fluorescence spectrophotometer (DP-6500). Unless
otherwise stated, all measurements were carried out using poly-
styrene disposable cuvettes (1 cm path length, Sarstedt) with an
1 :1 (v/v) acetonitrile/water mixture as the solvent system and for
each measurement micromolar concentrations were used. For the
determination of fluorescence quantum yields, a Hamamatsu
Photonics C11347 – Absolute PL quantum yield spectrometer was
used with 0.8 mL clear flat base vials (8 mm crimp, Thermo
Scientific). The lifetime measurements were carried out applying a
tunable fiber laser (FemtoFiber pro TVIS, TOPTICA Photonics, λexc=
490 nm) with a self-made TCSCP electronic. A bandpass filter (HQ
525/50, AHF analysis technique) was used for the filtration of the
laser light. The detection occurred with a combination of a single
photon-avalanche detector (PDM100ct SPAD, Micro Photon Device)
and a photon counting device (PicoHarp300, Pico Quant). The IRF
(instrumental response function) was measured with a diluted
colloidal LUDOX solution (LUDOX TM 50, Sigma Aldrich, λem=
470 nm, IRF (FWHM) ~100 ps) with an optical density filter of 1.0.
Fluorescence lifetimes were analyzed with the Sympho Time 64
software (Pico Quant).[71] All instruments measuring radioactivity
were calibrated and maintained in accordance with previously
reported routine quality-control procedures.[72] Radioactivity was
measured using an Activimeter ISOMED 2010 (Nuklear-Medizintech-
nik, Dresden, Germany). For accurate quantification of radioactivity,
experimental samples were counted for 1 min on a calibrated
Perkin Elmer (Waltham, MA, USA) 2480 Automatic Wizard Gamma
Counter by using a dynamic energy window of 400–600 keV for
fluorine-18 (511 keV emission). Statistical analyses (Student’s t-test,





yl)-butyric acid was synthesized according to literature procedure
with minimal modifications during the workup.[63,64] Yield: 55%. 1H-
NMR (400 MHz, CDCl3): δ=6.07 (s, 2H, 2xCH), 3.01–3.05 (m, 2H,
CH2), 2.56 (t,
3J=7.28 Hz, 2H, CH2), 2.52 (s, 6H, 2xCH3), 2.43 (s, 6H,
2xCH3), 1.94-2.02 (m, 2H, CH2) ppm.
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177.8, 154.3, 144.6, 140.3, 131.4, 121.8, 33.9, 27.3, 26.5, 16.3,
14.4 ppm. 19F-NMR (377 MHz, CDCl3): δ=-146.55 (m, 2F, BF2) ppm.
ESI-MS calcd m/z for C17H20N2O2BF2
  : 333.16, found: 333.16.
Compound 2
4-(4,4-Difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-inda-cene-8-
yl)-butyric-N-hydroxy-succinimide-ester was synthesized according
to the literature.[63,73] Yield: quant. 1H-NMR (400 MHz, CDCl3): δ=
6.06 (s, 2H, 2xCH), 3.05–3.09 (m, 2H, CH2), 2.83 (bs, 4H, 2xCH2), 2.79
(t, 3J=7.28 Hz, 2H, CH2), 2.50 (s, 6H, 2xCH3), 2.42 (s, 6H, 2xCH3),
2.04–2.06 (m, 2H, CH2) ppm.
13C-NMR (100 MHz, CDCl3): δ=171.1,
168.9, 167.7, 154.3, 144.0, 140.4, 131.3, 121.8, 60.3, 30.8, 26.9, 26.1,
25.5, 16.3, 14.4, 14.1 ppm. 19F-NMR (377 MHz, CDCl3): δ=-146.46 (m,
2F, BF2) ppm. ESI-MS calcd m/z for C21H24N3O4BF2
+ : 431.25, found:
431.26. Crystallographic data are given in the Supporting Informa-
tion.
Preparation of resin immobilized PSMA-binding motif Linker
conjugation and resin cleavage
The preparation of the 2-chlorotritylchlorid resin-immobilized
PSMA-binding motif Glu-CO-Lys as well as the conjugation of the
respective spacers were performed according to the literature with
minor modifications using standard Fmoc-chemistry starting with
Fmoc-L–Lys(Alloc)-OH.[45,50] The activation of L-glutamic acid-di-tert-
butyl ester for urea-coupling was carried out with 1,1’-
carbonyldiimidazole.[58]
General procedures for the synthesis of PSMA-BODIPY
bioconjugates 3–6
The final bioconjugates were prepared in solution.
Route A
In a typical reaction, a solution of 1 (1 eq.) and HATU (0.9 eq.)
containing N,N'-diisopropylethylamine (2 eq.) in dry DMF (1 mL)
was added to a solution of the crude precursor (1 eq.) in dry DMF
(1 mL). The dark orange solution was stirred for 2 h at 25 °C
quenched with water (0.1% TFA) and purified by semi-preparative
HPLC.
Route B
For the NHS-Ester coupling, a solution of 2 (1 eq.) and N,N'-
diisopropylethylamine (2 eq.) in dry DMF (1 mL) was added to a
solution of the amino acid precursors (1 eq.) at room temperature.
The dark orange solution was stirred for 2 h at 25 °C quenched with
water (0.1% TFA) and purified by semi-preparative HPLC.
Compound 3
According to general procedure starting with resin immobilized
Glu-CO-Lys (100 mg, 0.082 mmol). Gradient: 50% to 60% B in
15 min at a flow rate of 7 mL ·min  1. Retention times: tR (semi-
preparative HPLC): 11.75 min, tR (analytical HPLC): 11.26 min, Yield:
20 mg (0.031 mmol, 38%) of an orange solid. 1H-NMR (400 MHz,
CD3OD): δ=6.14 (s, 2H, 2xCH), 4.29 (2xdd,
3Jcis=5.02 Hz,
3Jtrans=
8.53 Hz, 3Jcis=4.77 Hz,
3Jtrans=8.28 Hz, 2H, 2xCCH) 3.19 (td,
2J=
1.25 Hz, 3J=7.03 Hz, 2H, CH2), 3.02–3.07 (m, 2H, CH2), 2.46 (s, 6H,
2xCH3), 2.44 (s, 6H, 2xCH3), 2.38–2.43 (m, 4H, 2xCH2), 2.11–2.17 (m,
1H, CH), 1.83–1.95 (m, 4H, 2xCH, CH2), 1.62-1.69 (m, 1H, CH), 1.51–
1.57 (m, 2H, CH2), 1.41–1.48 (m, 2H, CH2) ppm.
13C-NMR (100 MHz,
CD3OD): δ=176.6, 175.0, 155.1, 154.9, 154.1, 147.2, 142.6, 132.6,
122.9, 54.1, 53.7, 40.2, 37.2, 31.2, 30.0, 29.4, 29.0, 28.7, 23.9, 16.7,
14.6 ppm. 19F-NMR (377 MHz, CD3OD) δ=-148.29 (m, 2F, BF2) ppm.
LR-ESI-MS calcd m/z for C29H41N5O8BF2
+ : 636.3, found: 636.5.
Compound 4
According to general procedure starting with resin immobilized
Glu-CO-Lys-Ahx (100 mg, 0.068 mmol). Gradient: 50% to 60% B in
15 min at a flow rate of 7 mL ·min  1. Retention times: tR (semi-
preparative HPLC): 11.80 min, tR (analytical HPLC): 11.39 min, Yield:
20 mg (0.027 mmol, 39%) of an orange solid. 1H-NMR (400 MHz,
CD3OD): δ=6.14 (s, 2H, 2xCH), 4.24–4.33 (2xdd, 2x
3Jcis=5.02 Hz, 2x
3Jtrans=8.53 Hz, 2H, 2xCH), 3.18 (t,
3J=6.78 Hz, 2H, CH2), 3.13 (t,
3J=
6.78 Hz, 2H, CH2), 3.03–3.08 (m, 2H, CH2), 2.45 (s, 12H, 4xCH3), 2.36–
2.41 (m, 4H, 2xCH2), 2.15–2.21 (m, 3H, CH, CH2), 1.84–1.95 (m, 4H,
2xCH, CH2), 1.58–1.66 (m, 3H, CH, CH2), 1.48–1.55 (m, 4H, 2xCH2),
1.33–1.42 (m, 4H, 2xCH2) ppm.
13C-NMR (100 MHz, CD3OD): δ=
176.6, 176.3, 175.0, 160.3, 155.4, 147.4, 147.1, 142.6, 132.8, 122.9,
54.1, 53.3, 40.5, 40.2, 37.2, 37.1, 33.3, 31.2, 30.2, 30.0, 29.4, 29.0, 28.7,
27.7, 26.8, 24.1, 16.7, 14.6 ppm. 19F-NMR (377 MHz, CD3OD) δ=
  148.01 (m, 2F, BF2) ppm. LR-ESI-MS calcd m/z for C35H52N6O9BF2
+ :
749.4, found: 749.7.
Boron difluoride-free compound 4 -BF2
Compound 4 (10 mg, 0,013 mmol) was dissolved in 95% TFA (2 mL)
and stirred for 2 h at r.t. After incubation, the mixture was purified
using a SepPak C18 cartridges (Waters) and eluted using 50%
aqueous ethanol. Retention time: tR (analytical HPLC): 8.91 min,




According to general procedure starting with resin immobilized
Glu-CO-Lys-Ahx-Ahx (100 mg, 0.062 mmol). Gradient: 75% to 95%
B in 15 min at a flow rate of 6 mL ·min  1. Retention times: tR (semi-
preparative HPLC): 9.43 min, tR (analytical HPLC): 11.50 min. Yield:
20 mg (0.023 mmol, 37%) of an orange solid. 1H-NMR (400 MHz,
CD3OD): δ=6.14 (s, 2H, 2xCH), 4.24–4.26 (m, 1H, CH), 4.31–4.32 (m,
1H, CH), 3.11–3.20 (m, 6H, 3xCH2), 3.02–3.06 (m, 2H, CH2), 2.46 (s,
6H, 2xCH3), 2.44 (s, 6H, 2xCH3), 2.36–2.40 (m, 4H, 2xCH2), 2.16–2.19
(m, 5H, CH, 2xCH2), 1.89–1.96 (m, 4H, 2xCH, CH2), 1.60–1.62 (m, 3H,
CH, CH2), 1.48–1.53 (m, 8H, 4xCH2), 1.32–1.36 (m, 6H, 3xCH2) ppm.
13C-NMR (100 MHz, CD3OD): δ=174.6, 174.5, 173.5, 173.4, 153.7,
140.8, 131.2, 131.1, 121.2, 120.1, 51.4, 38.0, 35.5, 35.4, 29.4, 28.0,
27.6, 27.1, 26.9, 26.7, 26.0, 25.6, 25.1, 24.8, 21.8, 14.6, 12.4 ppm. 19F-
NMR (377 MHz, CD3OD) δ=   148.72 (m, 2F, BF2) ppm. LR-ESI-MS
calcd m/z for C41H63N7O10BF2
+ : 862.5, found: 862.8.
Compound 6
According to general procedure starting with resin immobilized
Glu-CO-Lys-2-Nal-Amc (100 mg, 0.058 mmol). Gradient: 50% to
95% B in 15 min at a flow rate of 7 mL ·min  1. Retention times: tR
(semi-preparative HPLC): 9.40 min, tR (analytical HPLC): 12.96 min.
Yield: 25 mg (0.026 mmol, 44%) of an orange solid. 1H-NMR
(400 MHz, CD3OD): δ=7.74–7.78 (m, 3H, 3xAr-CH), 7.66 (s, 1H, Ar-
CH), 7.37–7.41 (m, 3H, 3xAr-CH), 6.14 (s, 2H, 2xCH), 4.64–4.69 (dd,
3J=6.72 Hz, 3J=8.80 Hz, 1H, CH) 4.29–4.33 (dd, 3J=4.89 Hz, 3J=
8.44 Hz, 1H, CH), 4.17–4.20 (dd, 3J=4.52 Hz, 3J=8.31 Hz, 1H, CH),
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CH2), 2.99–3.04 (m, 4H, 2xCH2), 2.45 (2xs, 12H, 4xCH3), 2.36–2.41 (m,
5H, CH, 2xCH2), 2.09–2.18 (m, 2H, 2xCH), 1.86–1.94 (m, 3H, CH, CH2),
1.77–1.80 (m, 2H, 2xCH), 1.66–1.72 (m, 2H, 2xCH), 1.52–1.58 (m, 2H,
2xCH), 1.33–1.39 (m, 6H, 3xCH2), 0.89–0.98 (m, 2H, CH2) ppm.
13C-
NMR (100 MHz, CD3OD): δ=175.8, 173.2, 154.1, 153.6, 145.5, 140.8,
134.4, 133.3, 132.4, 130.8, 129.2, 128.6, 127.4, 126.7, 122.9, 121.1,
56.0, 54.0, 53.2, 46.3, 44.1, 39.7, 39.1, 38.8, 37.6, 36.7, 31.6, 29.4, 28.7,
28.4, 24.4, 16.7, 14.6 ppm. 19F-NMR (377 MHz, CD3OD) δ=   148.01




UV/vis and fluorescence measurements
A solution of 1 (73.4 mg, 0.22 mmol) in TFA (1 mL) was stirred for
2 h. Every minute, an aliquot of this solution (1 μL) was diluted with
acetonitrile (3 mL) and analyzed. After 1 h, the measurement-
interval was expanded to 5 min. One additional measurement was
performed after 24 h. To determine the effect of SnCl4, 1.22 mg
(3.65 μmol) of 1 were dissolved in acetonitrile (200 μL) and 20 μL of
this stock-solution were then mixed with 1 mL of a 1 M SnCl4
solution in acetonitrile. The absorption and fluorescence spectra of
the reaction mixture were recorded every 32 s (absorption scan or
fluori scan program) in a Hellma optical glass cuvettes (OS®) over a
period of 40 min.
HPLC studies
For analytical HPLC measurements of the dye stability, compound 1
(1 mg) was mixed with 95% aqueous TFA (1 mL) and incubated at
r.t. for 2 h. Fractions were collected manually and analyzed using
mass spectroscopy.
Radiolabeling of BODIPY-PSMA bioconjugates
Radiolabeling of the bioconjugates with [18F]F  was performed
manually. [18F]fluoride for radiolabeling was separated from the
irradiated [18O]H2O-containing solution by passage through an
anion-exchange cartridge (Waters Accel Plus QMA Cartridge Light).
The [18F]fluoride loaded anion exchange-cartridge was transferred
to a Wheaton-vial, eluted with tetraethylammonium bicarbonate
(TEAB) (25 mg) in acetonitrile/water (1 mL, 95 :5), washed with
acetonitrile (1 mL), and placed inside the heating block. [18F]F-TEA
was dried by azeotropic distillation with dry acetonitrile (3×2 mL)
under a gentle stream of argon at 95 °C and stored under argon in
dry acetonitrile. For a typical Lewis-acid assisted isotopic 19F/18F
exchange, 37 μL of a SnCl4 stock solution (1 M, in dry acetonitrile,
100 eq.) were added to 100 μL of the corresponding conjugate
stock solution in dry acetonitrile, followed by the addition of 300
MBq [18F]F-TEA in 100 μL dry acetonitrile. The mixture was
incubated for 15 min at r.t. and quenched by addition of a sodium
hydroxide solution (0.1 M, 4 mL) and purified by passage through a
SepPak C18 cartridge (Waters). After rinsing with a sodium hydroxide
solution (2 mL) and water (2 mL), the final product was eluted with
2 mL 50% aqueous ethanol. Radiochemical purities were >99%
and the mean radiochemical yields (RCY) were 20–30%. The mean
molar activities for all compounds were Am ~0,7 MBq ·nmol
  1.
In vitro characterization
Lipophilicity (log Doct/PBS) measurements
For log Doct/PBS measurements, 1–2 MBq of [
18F]F-3, [18F]F-4, [18F]F-5
and [18F]F-6 in 5 μL 50% aqueous ethanol were added to a mixture
of phosphate buffered saline pH 7.4 (PBS) (495 μL) and octanol
(500 μL). Samples were shaken for 30 min at r.t., centrifuged at
13,200 rpm for 5 min and 100 μL of each phase were counted using
a gamma counter. Experiments were performed in triplicate.
Stability measurements
For each experiment, ~5 MBq (10 μL) of [18F]F-4 were added to
phosphate buffered saline pH 7.4 (90 μL). At selected time points,
20 μL aliquots were taken from the solution and analyzed by HPLC.
The percentage of intact [18F]F-4 was calculated from the HPLC
chromatograms. All experiments were performed in triplicate.
Cell culture
LNCaP cells (DSMZ, Braunschweig, Germany) were cultured at 37 °C
in a 5% CO2 atmosphere (RPMI medium containing 10% fetal
bovine serum, 1% 10,000 U ·mL  1 penicillin and 10,000 U ·mL  1
streptomycin, 1% sodium-pyruvate 100 mM).
Competitive binding assay
The binding affinities of 3, 4, 5, 6 and boron difluoride-free 4 were
determined by a cell-based competitive binding assay in the human
prostate cancer cell line LNCaP with [177Lu]Lu-PSMA-617 as the
radioligand as previously described.[65] Binding assays were per-
formed in 24-well plates precoated with poly-L-lysine. Briefly, each
compound at different concentrations (0–10,000 nM) was incubated
for 2 h at r.t. with [177Lu]Lu-PSMA-617 (30,000 cpm·well  1) and 2×
105 LNCaP cells per well. After incubation, cells were washed three
times with ice cold binding buffer and cell-associated activity
recovered by addition of 1 M NaOH. Radioactivity was measured by
a gamma counter and data fitted using non-linear regression
(GraphPad Prism). Experiments were performed two times in
triplicate.
Cell internalization assay
For cell internalization, LNCaP cells were seeded at a density of 106
cells per well in 6-well plates and incubated overnight with RPMI-
medium with GlutaMAX containing 10% fetal bovine serum, 1%
10,000 U ·mL  1 penicillin and 10,000 U ·mL  1 streptomycin, and 1%
sodium-pyruvate 100 mM. After 24 h, the medium was removed
and the cells were washed with PBS. Approximately 5 pmol of [18F]
F-4 were added to the cells (in triplicates) to give a final volume of
1.5 mL PBS in each well followed by incubation for 1 h at 37 °C, 5%
CO2. To determine nonspecific membrane binding and internal-
ization, excess of 2-(phoshonomethyl)-pentanedioic acid (2-PMPA)
(final concentration 1 μM) was added to the selected wells. At each
time point, the internalization was stopped by removing the
medium and washing the cells twice with ice-cold PBS. To remove
the receptor-bound radioligand, an acid wash was carried out twice
with a 0.1 M glycine buffer (pH 2.8) for 5 min on ice. Finally, cells
were solubilized with 1 M NaOH. Radioactivity of cell fractions
(supernatant, receptor-bound and internalized) was measured by a
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Microscopy
For structured illumination microscopy (SIM), 105 cells were seeded
on a poly-L-lysine coated coverslip (25 mm) in a 6-well-plate 24 h
before incubation at 37 °C, 5% CO2. After washing with PBS, the
cells were incubated with 4 in RPMI-medium (20 nM final concen-
tration for each well) for 15 min, 30 min as well as 60 min at
different temperatures. In a second series, incubation was repeated
with a final concentration of 100 nM. Blocking studies were
performed by incubation with 2-PMPA (20 mM final concentration)
for 30 min. After incubation, cells were washed with PBS and fixed
with a paraformaldehyde-solution (4%, in PBS, containing 1.8 mM
CaCl2 and 1.0 mM MgCl2) for 15 min at r.t. After fixation, two
washing steps with PBS and water followed. Cell staining with 4‘,6-
diamidino-2-diphenylindole dihydrochloride (DAPI) was performed
using 2 drops NucBlueTM Fixed Cell Stain ReadyProbesTM in a total
volume of 2 mL water for 10 min. For mounting, 1 drop of Pro-Long
Diamond Antifade Mountant per coverslip was used and incubated
for 5 min. The coverslips were stored at 4 °C for microscopy. The
membrane uptake and internalization of 4 was measured using a
SIM microscope (Carl Zeiss Elyra PS.1 microscope) using a 63×
objective (nA 1.43). DAPI was excited by a 405 nm laser and 4 with
a 488 nm laser. Raw data were processed for super resolution with
Zen2012 software (Carl Zeiss) and postprocessed and analyzed with
ImageJ v.1.53 for presentation.
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